There has probably been more interest in gestational diabetes in recent years. A few years ago, we became a national gestational diabetes collaboration group under the Society of Perinatal Medicine. On the other hand, our hospital is the diagnosis and treatment center of gestational diabetes in Shanghai, and we have been working on it for more than 20 years. Therefore, we have accumulated some of our own experience, and when it comes to gestational diabetes, there has been a great progress in the past few years, both domestically and abroad. The current situation in China is that, first of all, the research and attention to this area is uneven from one region to another, so what does this unevenness show? In other regions, the concept of gestational diabetes is not yet clear, and even screening tests for gestational diabetes have not yet been conducted. So this is an uneven performance. Another aspect is that the incidence of gestational diabetes is also uneven nationwide. In the last two years, we conducted a nationwide mapping survey, a 50 gram screening test and an OGTT test, and found that the incidence of this disease is very different in different regions. For example, the incidence of abnormal 50 gram screening in Shanghai is only about 8-10%, Beijing is about 20%, like the western region of Sichuan, it is about 35%. So from this data, it is possible that the incidence of gestational diabetes in our country is also extremely uneven. The reasons for this imbalance are not yet clear, whether it is a matter of diet, race, climate, environment, lifestyle, etc. The current research on gestational diabetes in China is mainly from several aspects, one is the clinical reports, such as the prognosis of children with gestational diabetes, the relationship between blood glucose and child prognosis. There are also some basic studies being conducted by some units, such as exploring the etiology of gestational diabetes, such as inflammation, tumor necrosis factor, and adipokines, which may be related to insulin resistance, because we know that insulin resistance may be a cause of gestational diabetes. This is a general domestic situation. The research on gestational diabetes in foreign countries has been done relatively more from the basic aspect, mainly to study the causes of gestational diabetes, probably from the aspect of molecular biology, and more emphasis has been placed on the relationship between good or bad glycemic control during pregnancy and the future of the child in adulthood or childhood or even preschool, adolescence or childbearing age up to middle age and old age. The long-term impact of the child. In recent years, a theory called Doha theory has been slowly accepted in China, which refers to the fetal origin of adult diseases. In terms of gestational diabetes, some relevant studies have been conducted. In recent years, many conferences have been held around the world, and we have introduced this concept into China, so there are now some units in China engaged in related research. Another is that with the use of insulin, there are now new insulins, such as ultra-short-acting insulin (a kind of insulin analog). I think that ultra-short-acting insulin has its advantages for gestational diabetes, because it has a very short onset time, about ten minutes, while ordinary insulin takes at least half an hour, so it has the advantage that you can eat while using insulin. There is also the issue of oral hypoglycemic drugs. Because we all know, gestational diabetes treatment, relying on insulin treatment can of course solve most of the problems, but after all, it is still a certain problem in terms of patient acceptance. So if there is an oral drug that is safe and effective in the future, then of course it is very good; however, in China we have not yet got a good validation of oral hypoglycemic drugs, not approved by the domestic FDA. However, in China, oral hypoglycemic drugs have not yet been validated and approved by the FDA. In some clinical studies conducted abroad, it was found that several oral hypoglycemic drugs can lower blood glucose very well in gestational diabetes without increasing fetal malformations or other complications of the mother. It is possible that in the near future, oral hypoglycemic agents may also be used as a common hypoglycemic agent, or a measure, in gestational diabetes.